ABL Texcell Diagnostics (formerly ABL Diagnostics) specializes in the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases (AIDS, viral hepatitis and tuberculosis) by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. Export accounts for 69.7% of net sales.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
06/11/26	€2.440	+1.67%	3,172
05/11/26	€2.400	-3.23%	1,008
04/11/26	€2.480	0.00%	875
03/11/26	€2.480	+1.64%	1,380
02/11/26	€2.440	+7.02%	12,452

Real-time Euronext Paris

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - ABL Texcell Diagnostics

Company calendar

Market Closed - Euronext Paris 19:55:00 06/11/2026 +03			5-day change	1st Jan Change
2.440 ^EUR	+1.67%		+7.02%	-18.67%

10-21	ABL Texcell Diagnostics Ends Proposed Acquisition of Vela's US, Singapore Operations	MT
10-20	ABL Texcell Diagnostics SA cancelled to acquire Vela Diagnostics Usa, Inc. and Vela Operations Singapore Pte Ltd. from VDH Holding Pte. Ltd.	CI

Market Cap	39.21M 43.72M 35.83M 32.71M 61.63M 4.11B 63.57M 432M 172M 2.19B 164M 161M 6.92B	P/E 2024	123x	P/E 2025	50x
Enterprise Value	40.14M 44.76M 36.69M 33.49M 63.1M 4.21B 65.08M 442M 176M 2.24B 168M 164M 7.09B	EV / Sales 2024	7,098,474x	EV / Sales 2025	6,185,843x
Free-Float	6.2%	Yield 2024	2.03%	Yield 2025	3.67%

Markets		Quality
Euronext Paris	ABLD	Real-time
CBOE	0OPO	Real-time
CBOE	FAUVp	Real-time
Deutsche Boerse AG	9BK0	Delayed
Börse Stuttgart	9BK0	Delayed

10-21	ABL Texcell Diagnostics Ends Proposed Acquisition of Vela's US, Singapore Operations	MT
10-20	ABL Texcell Diagnostics SA cancelled to acquire Vela Diagnostics Usa, Inc. and Vela Operations Singapore Pte Ltd. from VDH Holding Pte. Ltd.	CI
10-12	ABL Texcell Diagnostics to Acquire French Biotech Company IntegraGen	MT
10-12	ABL Diagnostics Société anonyme completed the acquisition of Business operations and assets of IntegraGen SA for ?0.1 million.	CI
10-01	ABL Diagnostics Revises Revenue Guidance for the Financial Year 2026	CI
09-22	ABL Texcell Diagnostics Signs LoI to Acquire Vela's US, Singapore Operations	MT
09-21	ABL Texcell Diagnostics SA signed a letter of intent to acquire Vela Diagnostics Usa, Inc. and Vela Operations Singapore Pte Ltd. from VDH Holding Pte. Ltd.	CI
09-18	ABL Diagnostics Shareholders Approve Name Change; Euronext Paris Listing to Remain	MT
09-17	ABL Diagnostics Société anonyme has Changed its Name to ABL Texcell Diagnostics	CI
09-11	ABL Diagnostics Société anonyme proposed to acquire Business operations and assets of IntegraGen SA.	CI
09-11	ABL Diagnostics Offers to Acquire IntegraGen Amid Reorganization Proceedings	MT
09-11	Abionyx Pharma Partners With ABL Diagnostics Division for Viral Safety Testing of CER-001	MT
09-10	Abionyx Pharma Enters into Strategic Partnership with TEXCELL (Abl Diagnostics) for Viral Safety and Clearance of Biologics	CI

ABL Texcell Diagnostics Stock

Stocks

ABLD

FR001400AHX6

Medical Equipment, Supplies & Distribution

Valuation: ABL Texcell Diagnostics

Chart: ABL Texcell Diagnostics

Latest news: ABL Texcell Diagnostics

Press Releases: ABL Texcell Diagnostics

News in other languages: ABL Texcell Diagnostics

Quotes and Performance

Price Extremes

Managers and Directors: ABL Texcell Diagnostics

Latest insider transactions

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

10-20	ABL Texcell Diagnostics Announces Termination of Vela Diagnostics Letter of Intent	BU
10-19	ABL Texcell Diagnostics Strengthens the Foundations of a Stable Shareholder Base and Pursues Its Growth Strategy	BU
10-16	ABL Texcell Diagnostics: Notice of Appeal by the Public Prosecutor Regarding the IntegraGen Transfer Judgment	BU
10-12	ABL Texcell Diagnostics Strengthens Its Presence at Genopole and Opens a New Chapter in Precision Oncology With the Acquisition of IntegraGen’s Assets and Operations	BU
10-08	ABL Texcell Diagnostics Announces Availability of All Invest Securities Research Flash Note #8	BU

10-21	Bourse : EssilorLuxottica qui rit, Michelin, Eurofins et Carrefour qui pleurent
10-21	SpaceX et Super Micro en pompiers de la tech
10-20	ABL TEXCELL DIAGNOSTICS ANNONCE LA RÉSILIATION DE LA LETTRE D’INTENTION RELATIVE À VELA DIAGNOSTICS
10-19	ABL TEXCELL DIAGNOSTICS RENFORCE LES CONDITIONS D’UN ACTIONNARIAT STABLE ET POURSUIT SA STRATÉGIE DE CROISSANCE
10-16	ABL TEXCELL DIAGNOSTICS : DÉCLARATION D’APPEL DU MINISTÈRE PUBLIC RELATIVE AU JUGEMENT DE CESSION D’INTEGRAGEN

1 day	+1.67%
1 week	+7.02%
Current month	+7.02%
1 month	+9.91%
3 months	-1.61%
6 months	+9.91%
Current year	-18.67%

1 week	2.32	2.52
1 month	2.18	2.6
Current year	2.1	5
1 year	2.1	5
3 years	2.1	9.7
5 years	1.99	26
10 years	1.28	26

Director	Title	Age	Since
Noemie Sadoun CHM	Chairman	-	-
Laure Raffaelli BRD	Director/Board Member	-	-
Deborah Szafir BRD	Director/Board Member	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/28/26 A	Advanced Biological Laboratories SA	Sell	Company	-60,000	0.3723%
7/20/26 A	Advanced Biological Laboratories SA	Sell	Company	-65,616	0.4072%
7/6/26 A	Advanced Biological Laboratories SA	Sell	Company	-62,308	0.3867%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABL TEXCELL DIAGNOSTICS	+1.67%	+7.02%	-17.01%	-74.85%	43.72M
ABBOTT LABORATORIES	-3.23%	+3.51%	-13.00%	+15.96%	190B
MEDTRONIC PLC	-2.90%	+5.45%	+10.41%	+40.45%	125B
STRYKER CORPORATION	-2.75%	+11.65%	-8.47%	+18.50%	124B
ESSILORLUXOTTICA	+0.96%	+5.15%	-37.16%	+12.09%	99.31B
CENCORA, INC.	-1.80%	+0.82%	-7.52%	+70.12%	63.65B
BECTON, DICKINSON AND COMPANY	-0.78%	+7.07%	+19.14%	-17.27%	57.71B
IDEXX LABORATORIES, INC.	+0.79%	+22.65%	-4.57%	+60.02%	53.26B
HOYA CORPORATION	-6.98%	-14.56%	-11.97%	+46.23%	47.03B
ALCON INC.	-2.36%	+3.72%	+3.86%	-7.99%	36.15B
Average	-1.74%	+5.44%	-6.63%	+16.33%	79.62B
Weighted average by Cap.	-2.20%	+5.71%	-7.49%	+25.27%

	2024	2025
Net sales	5.87 6.54 5.36 4.9 9.23 615.16 9.52 64.66 25.78 328.24 24.56 24.04 1.04K	7.97 8.88 7.28 6.65 12.52 834.87 12.92 87.75 34.99 445.47 33.34 32.62 1.41K
Net income	285K 318K 261K 238K 448K 29.89M 462K 3.14M 1.25M 15.95M 1.19M 1.17M 50.35M	987K 1.1M 902K 823K 1.55M 103M 1.6M 10.87M 4.33M 55.18M 4.13M 4.04M 174M
Net Debt	2.02M 2.26M 1.85M 1.69M 3.18M 212M 3.28M 22.29M 8.89M 113M 8.47M 8.29M 357M	933K 1.04M 852K 778K 1.47M 97.75M 1.51M 10.27M 4.1M 52.16M 3.9M 3.82M 165M